ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag cancer fda disease medicine pharma

Pharma Cooperates to Achieve Precision Medicine
Catherine Offord | Feb 1, 2017 | 7 min read
The challenges of adapting drug development to the age of personalized therapies encourage collaboration among industry players.
Matthew Disney
A Quest to Drug RNA
Ida Emilie Steinmark, PhD | Sep 8, 2023 | 5 min read
Matthew Disney’s idea of small molecules that target RNA once seemed fanciful. Now, even the pharma industry is pursuing it
The Vaginal Microbiome is Finally Getting Recognized
Hannah Thomasy, PhD, Drug Discovery News | Sep 25, 2023 | 10+ min read
Vaginal dysbiosis has long been a taboo subject, but studying and optimizing the vaginal microbiome could be a game changer for women's health.
Concerns over Efficacy and Cost of Muscle Wasting Treatments
Ruth Williams | Nov 11, 2020 | 5 min read
Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.
FDA Approves Gene Therapy for Spinal Muscular Atrophy
Ashley Yeager | May 27, 2019 | 3 min read
At $2 million for a single dose, Novartis’s Zolgensma is the most expensive medicine to date, but still less expensive over a lifetime than another approved drug for the rare genetic disease.
Lazarus Drugs
Kate Yandell | Feb 1, 2015 | 8 min read
While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.
 
Avant-Garde Science
Mary Beth Aberlin | Jun 1, 2012 | 3 min read
Why naked mole-rats and experimental gene therapies remind me of groundbreaking artists.
Pharma Looks to Inflammasome Inhibitors as All-Around Therapies
Rachael Moeller Gorman | Apr 1, 2021 | 10+ min read
Many major biopharmaceutical companies are developing or acquiring drugs that target the NLRP3 inflammasome, a large intracellular complex that researchers say can spark inflammation and stoke diseases of lifestyle and aging.
Do-It-Yourself Medicine
Jef Akst | Mar 1, 2013 | 10+ min read
Patients are sidestepping clinical research and using themselves as guinea pigs to test new treatments for fatal diseases. Will they hurt themselves, or science?
Make Mine Rare
Megan Scudellari | Aug 1, 2011 | 7 min read
With mounting interest from biotechs, Big Pharma, and the federal government, research on rare diseases is burgeoning.

Run a Search

ADVERTISEMENT